A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 22 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 May 2019.
    • 15 Mar 2017 Planned End Date changed from 1 Jan 2018 to 1 May 2019.
    • 15 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top